A Primer of Collagen Biology: Synthesis, Degradation, Subtypes, and Role in Dupuytren’s Disease

Hart, Susan Emeigh

doi:10.1007/978-3-642-22697-7_17

Cited by 3 publications

(2 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCH is a purified mixture of two microbial collagenases isolated from Clostridium histolyticum, including AUX‐I functionally classified as Class I collagenase and AUX‐II functionally classified as Class II collagenase, that enzymatically degrade the predominant collagen types found in PD plaques [11,22,23]. Clostridium histolyticum bacterial collagenases can be differentiated from mammalian collagenases (i.e., matrix metalloproteinases) in their ability to cleave collagen at many sites vs. a single cleavage [10,24–26]. The two classes of bacterial collagenases included in CCH have shown complementary effects through different initial cleavage of sites on the collagen triple helix as well as synergistic activity in degradation of collagen [11,12].…”

Section: Resultsmentioning

confidence: 99%

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Gelbard

Chagan²,

Tursi³

2015

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction The conception of collagenase Clostridium histolyticum (CCH) as treatment for Peyronie's disease (PD) was a vital first step in providing a nonsurgical, minimally invasive FDA-approved treatment for men with PD. Aim To review the origins, clinical research history, and ultimately FDA approval of collagenase as PD treatment. Methods A PubMed search using (Peyronie's or Peyronie) AND collagenase, and limited to clinical research studies, returned nine papers that were examined in the current review. Results Collagenase as a PD treatment arose in response to a lack of effective nonsurgical treatments and the incomplete understanding of underlying PD etiology. Awareness of dense collagen in PD scarring and parallel initial exploration of collagenase to treat herniated lumbar discs coincided with and inspired laboratory-based investigation of collagenase effects on excised PD plaque tissue. The foundational conceptual work and the critical development of purified injectable collagenase allowed the pursuit of clinical studies. Progression of clinical studies into large-scale robust trials culminated in two important outcomes: development of the first validated, PD-specific measure of psychosexual function, the Peyronie's Disease Questionnaire, and the first FDA-approved treatment for PD. Conclusions Collagenase therapy began as an attempt to modify the structure of PD-related tunica albuginea scarring, despite the lack of a fundamental understanding of the scar's origin. If we wish to advance PD treatment beyond this first effective step, the future needs to bring us full circle to the starting point: We need a greater understanding of the control of collagen deposition and wound healing in men with PD.

show abstract

Section: Resultsmentioning

confidence: 99%

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Gelbard

Chagan²,

Tursi³

2015

The Journal of Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…[27]. In in vivo experiments as well as in healthy tissue, there is a continuous process of collagen synthesis and collagen degradation, and both are precisely balanced to maintain normal tissue or biomaterial architecture [6,12,16]. Thus, in the present model, it is considered that the amount of collagen produced by cells is balanced with those degraded, so the net rate of ECM production is considered null [13], f ρ = 0.…”

Section: Law Of Conservation Of Species Q(x T)mentioning

confidence: 99%

Structural biology response of a collagen hydrogel synthetic extracellular matrix with embedded human fibroblast: computational and experimental analysis

Manzano

Moreno‐Loshuertos

Doblaré

et al. 2015

Med Biol Eng Comput

View full text Add to dashboard Cite

Adherent cells exert contractile forces which play an important role in the spatial organization of the extracellular matrix (ECM). Due to these forces, the substrate experiments a volume reduction leading to a characteristic shape. ECM contraction is a key process in many biological processes such as embryogenesis, morphogenesis and wound healing. However, little is known about the specific parameters that control this process. With this aim, we present a 3D computational model able to predict the contraction process of a hydrogel matrix due to cell-substrate mechanical interaction. It considers cell-generated forces, substrate deformation, ECM density, cellular migration and proliferation. The model also predicts the cellular spatial distribution and concentration needed to reproduce the contraction process and confirms the minimum value of cellular concentration necessary to initiate the process observed experimentally. The obtained continuum formulation has been implemented in a finite element framework. In parallel, in vitro experiments have been performed to obtain the main model parameters and to validate it. The results demonstrate that cellular forces, migration and proliferation are acting simultaneously to display the ECM contraction.

show abstract

Treatment for Dupuytren’s Disease: An Overview of Options

Rijssen

Werker

2011

Dupuytren’s Disease and Related Hyperproliferative Disorders

View full text Add to dashboard Cite

A Primer of Collagen Biology: Synthesis, Degradation, Subtypes, and Role in Dupuytren’s Disease

Cited by 3 publications

References 75 publications

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Structural biology response of a collagen hydrogel synthetic extracellular matrix with embedded human fibroblast: computational and experimental analysis

Treatment for Dupuytren’s Disease: An Overview of Options

Contact Info

Product

Resources

About